278 related articles for article (PubMed ID: 18559604)
1. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.
Lee SB; Hassan M; Fisher R; Chertov O; Chernomordik V; Kramer-Marek G; Gandjbakhche A; Capala J
Clin Cancer Res; 2008 Jun; 14(12):3840-9. PubMed ID: 18559604
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging.
Chernomordik V; Hassan M; Lee SB; Zielinski R; Gandjbakhche A; Capala J
Mol Imaging; 2010 Aug; 9(4):192-200. PubMed ID: 20643022
[TBL] [Abstract][Full Text] [Related]
3. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
4. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
6. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
[TBL] [Abstract][Full Text] [Related]
7. Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging.
Zielinski R; Hassan M; Lyakhov I; Needle D; Chernomordik V; Garcia-Glaessner A; Ardeshirpour Y; Capala J; Gandjbakhche A
PLoS One; 2012; 7(7):e41016. PubMed ID: 22911732
[TBL] [Abstract][Full Text] [Related]
8. Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer.
Yamaguchi H; On J; Morita T; Suzuki T; Okada Y; Ono J; Evdokiou A
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830099
[TBL] [Abstract][Full Text] [Related]
9. In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging.
Hassan M; Chernomordik V; Zielinski R; Ardeshirpour Y; Capala J; Gandjbakhche A
Mol Imaging; 2012 Jun; 11(3):177-86. PubMed ID: 22554482
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
11. High-sensitivity detection of breast tumors in vivo by use of a pH-sensitive near-infrared fluorescence probe.
Mathejczyk JE; Pauli J; Dullin C; Resch-Genger U; Alves F; Napp J
J Biomed Opt; 2012 Jul; 17(7):076028. PubMed ID: 22894511
[TBL] [Abstract][Full Text] [Related]
12. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]